Palvella Secures FDA Rolling Review for Rare Disease Drug
WAYNE, PA — Palvella Therapeutics (Nasdaq: PVLA) has received U.S. Food and Drug Administration authorization for rolling review of its New Drug Application for QTORIN rapamycin, a step that could …
Palvella Secures FDA Rolling Review for Rare Disease Drug Read More